RHONDA KAUFMAN, M.D.
Osteopathic Medicine in Rahway, NJ
License number
New Jersey 55779
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
2
126 EAST Lincoln Ave Ry34A512 Merck & Co., Rahway, NJ 07065
35 Running Brook Rd, Bridgewater, NJ 08807
35 Running Brook Rd, Bridgewater, NJ 08807
Phone
(732) 594-5854
Organization information
See more information about RHONDA KAUFMAN at bizstanding.comRhonda Kaufman MD
126 E Lincoln Ave, Rahway, NJ 07065
Industry:
Internist
Phone:
(732) 594-5854 (Phone)
Rhonda Kaufman
Professional information
Rhonda Kaufman, Rahway NJ
Specialties:
Internist
Address:
126 E Lincoln Ave, Rahway, NJ 07065
Education:
Boston University, School of Medicine - Doctor of Medicine
VA Boston Healthcare System-Jamaica Plain Campus - Residency - Internal Medicine
VA Boston Healthcare System-Jamaica Plain Campus - Residency - Internal Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine
Dr. Rhonda Kaufman, Rahway NJ - MD (Doctor of Medicine)
Specialties:
Internal Medicine
Address:
126 E Lincoln Ave STE RY34A512, Rahway 07065
(732) 594-4000 (Phone), (908) 236-1701 (Fax)
(732) 594-4000 (Phone), (908) 236-1701 (Fax)
Certifications:
Internal Medicine, 1986
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Boston University School of Medicine
Graduated: 1983
Boston Va Med Center
Va Med Ctr
Tufts Med Center
Boston University School of Medicine
Graduated: 1983
Boston Va Med Center
Va Med Ctr
Tufts Med Center
Rhonda Kaufman, Rahway NJ
Specialties:
Internal Medicine, Clinical Pharmacology
Work:
Merck & Co.
126 E Lincoln Ave, Rahway, NJ 07065
126 E Lincoln Ave, Rahway, NJ 07065
Education:
Boston University(1983)
Therapeutic Combinations Comprising Poly (Adp-Ribose) Polymerases Inhibitor
US Patent:
2006007, Apr 6, 2006
Filed:
Sep 20, 2005
Appl. No.:
11/231470
Inventors:
Heidi Marie Steinfeldt - San Diego CA, US
Theodore James Boritzki - San Diego CA, US
Alan Hilary Calvert - Blaydon-on-Tyne, GB
Nicola Jane Curtin - Rowlands Gill, GB
Mohamed Raza Dewji - Harrow, GB
Zdenek Hostomsky - La Jolla CA, US
Christopher Jones - Gosforth, GB
Rhonda Kaufman - Bridgewater NJ, US
Karen Klamerus - San Diego CA, US
David Richard Newell - Humshaugh, GB
Elizabeth Ruth Plummer - Heddon-on-the-Wall, GB
Steven Reich - Del Mar CA, US
Ian Stratford - Manchester, GB
Huw David Thomas - Houghton-le-Spring, GB
Kay Janine Williams - Middleton, GB
Theodore James Boritzki - San Diego CA, US
Alan Hilary Calvert - Blaydon-on-Tyne, GB
Nicola Jane Curtin - Rowlands Gill, GB
Mohamed Raza Dewji - Harrow, GB
Zdenek Hostomsky - La Jolla CA, US
Christopher Jones - Gosforth, GB
Rhonda Kaufman - Bridgewater NJ, US
Karen Klamerus - San Diego CA, US
David Richard Newell - Humshaugh, GB
Elizabeth Ruth Plummer - Heddon-on-the-Wall, GB
Steven Reich - Del Mar CA, US
Ian Stratford - Manchester, GB
Huw David Thomas - Houghton-le-Spring, GB
Kay Janine Williams - Middleton, GB
International Classification:
A61K 31/55
US Classification:
514212060
Abstract:
This invention generally relates to use of 8-fluoro-2{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one represented by formula 1 as a chemosensitizer that enhances the efficacy of cytotoxic drugs or radiotherapy.
This invention provides pharmaceutical combinations of 8-fluoro-2{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, or a pharmaceutically acceptable salt thereof and at least one additional therapeutic agent, kits containing such combinations and methods of using such combinations to treat subjects suffering from diseases such as cancer.